BRAF StripAssay
ViennaLab’s BRAF StripAssay® offer a solution for the rapid identification of critical BRAF gene mutations, specifically focusing on codons 600 and 601. Employing a methodology that combines polymerase chain reaction (PCR) and reverse-hybridization, the assay facilitates targeted therapeutic interventions in malignancies such as metastatic colorectal cancer, advanced non-small cell lung cancer, melanoma, and thyroid cancer.
Quote-based, no public pricing. Add to your quote and our specialists put together a proposal with the right documentation, typically within 24 hours.
This kit in detail
ViennaLab’s BRAF StripAssay® offer a solution for the rapid identification of critical BRAF gene mutations, specifically focusing on codons 600 and 601. Employing a methodology that combines polymerase chain reaction (PCR) and reverse-hybridization, the assay facilitates targeted therapeutic interventions in malignancies such as metastatic colorectal cancer, advanced non-small cell lung cancer, melanoma, and thyroid cancer.
- Rapid Identification
- High Precision
- Targeted Therapy
- Prognostic Assessment
- Clinical Trials
- Multi-Cancer Applicability
BRAF StripAssay for Targeted Oncological Interventions
Role and Significance of BRAF
The BRAF gene plays an integral role in cellular signaling pathways, primarily influencing cellular proliferation and differentiation. Within the realm of metastatic colorectal cancer (mCRC), the BRAF V600 mutational status is ascertained concurrently with RAS mutational status to enable precise prognostic assessment and, where applicable, to ascertain eligibility for clinical trials.
For patients with metastatic melanoma and advanced non-small cell lung cancer, pre-treatment testing for BRAF V600 mutations is recommended. Patients with positive mutational status are likely to derive benefit from specific BRAF inhibitor therapies such as dabrafenib, trametinib, and vemurafenib. Additionally, mutations within the BRAF gene contribute significantly to the pathogenesis and progression of thyroid cancer and melanoma.
Molecular Mechanism
The BRAF gene is a vital constituent of the Mitogen-Activated Protein Kinase (MAPK) pathway, serving as an intermediary in the transduction of signals from RAS oncogenes. Mutations in this gene, particularly those that augment kinase activity, can lead to incessant activation of transcription-mediated proliferation, thus encouraging neoplastic growth.
Methodological Framework
Designed for in vitro diagnostics, the BRAF StripAssays® employ a combination of polymerase chain reaction (PCR) and reverse-hybridization techniques. The methodology encompasses:
- DNA Isolation: Preliminary extraction of genomic DNA from cellular samples.
- PCR Amplification: Utilization of biotinylated primers for the amplification of target DNA segments.
- Reverse-Hybridization: Amplified DNA undergoes hybridization against allele-specific oligonucleotide probes, arrayed as parallel lines on a test strip.
The assay is proficient in identifying nine mutations in the BRAF gene, focusing specifically on codons 600 and 601.
- Biotinylated Primers: For specific amplification of target DNA sequences within the BRAF gene.
- Allele-Specific Oligonucleotide Probes: These are immobilized on a test strip and used for the reverse-hybridization process to identify specific mutations.
- DNA Isolation Kit
- PCR Mix
- Streptavidin-Alkaline Phosphatase: Used in the detection of bound biotinylated sequences on the test strip.
- Color Substrates
- Calibration Standards: Included for validating the results.
- Quality Control Material
Datasheets and regulatory documentation
Everything your quality team needs for evaluation and procurement.
Frequently paired with this kit
Other assays and instruments lab teams add alongside the BRAF StripAssay.
Add this kit to your quote
Tell us the platforms and throughput you’re planning for and our specialists will put together a clear proposal with the right documentation, no public pricing, just a considered answer.
